June 2, 2010 – Antiviral Drugs Advisory Committee
BLA – motavizumab (MedImmune)
Agenda: On June 2, 2010, the committee will discuss biologics license application (BLA) 125283, motavizumab, MedImmune, LLC, proposing an indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment